Estudo clínico fases 1-2 | Rilzabrutinibe, um inibidor BTK oral, na trombocitopenia imune.

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial – Massachusetts General Hospital

Comentário no Twitter

Rilzabrutinib had rapid and durable clinical activity in adults with immune thrombocytopenia, with low-level toxic effects. https://t.co/boWT4LpQkk pic.twitter.com/ZpNXHYL2Gv

— NEJM (@NEJM) April 18, 2022